Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China
Jianqiu Wu(Jiangsu Cancer Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Yu Hu(Wuhan Union Hospital), Yongping Song(First Affiliated Hospital of Zhengzhou University), Wei Li(Wuhan National Laboratory for Optoelectronics), Xiaohong Zhang(Harbin Engineering University), Mingzhi Zhang(Chinese Academy of Sciences), Xiaolin Li(Guangzhou University of Chinese Medicine), Wei Wang(The University of Texas MD Anderson Cancer Center), Ru Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhen Xiao, Hai Bai(Lanzhou Army General Hospital), Jishi Wang(Jiangsu Cancer Hospital), Weijing Zhang(Academy of Military Medical Sciences), Changping Wu(Soochow University), Yongzhi Zhuang(Daqing Oilfield General Hospital), Tongjian Cui(Fujian Medical University), Liping Su, Yuhuan Gao(Hebei Medical University), Yingmin Liang(Tang Du Hospital), Yun Zeng(Xidian University)
Cited by 27
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
|Molecular Cell|2007|731
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
|Science Immunology|2020|555